Herborium Receives Gents AB Distribution Agreement Renewal

Herborium Group, Inc. (Pink Sheets:HBRM), www.herborium.com, a Botanical Therapeutics™ company, during its shareholder conference call yesterday afternoon, announced that Gents, AB of Helsingborg, Sweden, renewed its distribution agreement to supply AcnEase® throughout Sweden.

"We are pleased that Gents, AB has renewed their distribution license and also secured the Swedish regulatory permit to sell AcnEase® as a natural medicine throughout Sweden," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "We expect to receive their first order before Thanksgiving.

"The top five markets in the European Union (EU) are roughly equivalent in size to the U.S. market. A key tactic in our 2011 marketing strategy includes adding new distributors to our current list of European partners and, the Swedish market serves an important role in establishing AcnEase throughout Northern Europe including Denmark, Finland, & Norway."

Swedish and European consumers are highly educated and very comfortable using natural, botanically based medicines and skincare products.Moreover, the European natural medicines regulatory environment has evolved and many EU countries now recognize natural medicinal products and natural medicine practitioners. Herborium is now poised to take advantage of this ready consumer base.

"We expect the Swedish agreement to add more than $100,000 in additional revenues to our bottom line in 2011. I look forward to soon announcing more agreements in this region," Olszewski concluded.

About Gents, AB

Gents, AB is an upscale distributor of health and personal care products specifically targeting male consumers. The men's personal care and cosmetic products industry is the fastest growing segment of the "vanity product" sector in the U.S. and Europe. For more information, please visit www.gents.com.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.  

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

CONTACT:  Herborium Group, Inc.
          Investor Relations
          Steve Haag
          [phone]